Proacta
CompanyUnited States
Proacta develops one asset, in phase 1 (PR104 in hepatocellular carcinoma). Mostly small molecule acting on DNA damage response and DNA repair; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 0
- Signals
Pipeline
1Hypoxia-activated prodrug converted to a DNA-crosslinking agent
Phase 1, Small molecule, DNA damage response, DNA repair, hepatocellular carcinoma
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Similar companies6